comparemela.com

Latest Breaking News On - Jill milne - Page 1 : comparemela.com

Astria Therapeutics, Inc (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript

Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript November 13, 2023 Astria Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.63 EPS, expectations were $-0.51. Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode. [Operator Instructions] As a […]

Andrea matthewsDavid shaw quantNoah clauserChristopher morabitoAndrew komjathyChief business officerChief financial officerPivotal phaseHedge fundsWall street analysts are crazy aboutBillionaire david shawQuant models love theseAtopic dermatitisChief commercial officerAndrea matthewsJill milne

Astria Therapeutics, Inc (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript

Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.

Andrew komjathyNoah clauserJill milneDavid shaw quantEun yangLiz higginsChristopher morabitoElizabeth higginsSam slutskySeema shorinAndrea matthewsAstria therapeutics incAstria therapeuticsCall transcript novemberAstria therapeutics quarter threeInvestor relations

Glenmark s subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio

Glenmark s subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Jill milneCyril kontoIchnos sciencesGlenmark pharmaceuticalsAstria therapeuticsAstria therapeutic

Glenmark arm inks licensing pact with Astria Therapeutics

With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company s prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.

Jill milneCyril kontoGlenmark pharmaceuticals ltd onIchnos sciencesPharmaceuticals ltdAstria therapeuticsManaging directorAstria therapeuticGlenmark pharmaceuticals

Glenmark Pharma subsidiary signs licensing deal for monoclonal antibody portfolio with US firm

Glenmark subsidiary Ichnos will receive up to $320 million in upfront, development, regulatory and sales milestone payments in addition to up to low double-digit royalties

Cyril kontoJill milneIchnos sciencesGlenmark pharmaceuticalsNational stock exchangeAstria therapeuticsLicense agreement

vimarsana © 2020. All Rights Reserved.